Compare Aon PLC (AON) vs GSK plc (GSK) Price & Performance

AON trades at $351.56, down 1.52% on the day, with a neutral technical signal and strong fundamentals including a 22.27% net income margin and consistent earnings beats. The stock shows robust profitability with ROE of 44.88% and revenue growth to $17.18B in 2025, though valuation multiples like a P/E of 19.65 and P/S of 4.37 reflect premium pricing. Recent news highlights institutional buying and Q2 2026 earnings beat, with organic revenue growth of 5% supporting positive sentiment.

Outlook remains favorable given earnings momentum and analyst consensus price target of $410, but risks include high valuation sensitivity and debt levels. The stock offers growth exposure with upside potential, balanced by execution risks in a competitive insurance brokerage sector.

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.